The Possible Influence of Antibiotics on Results of Bacillus Calmette-Guérin Intravesical Therapy for Superficial Bladder Cancer

No AccessJournal of Urology1 Aug 1991The Possible Influence of Antibiotics on Results of Bacillus Calmette-Guérin Intravesical Therapy for Superficial Bladder Cancer Ad P.M. Van Der Meijden, Bert Van Klingeren, Peter A. Steerenberg, Liesbeth C. De Boer, Wim H. De Jong, and Frans M.J. Debruyne Ad P.M. Van Der MeijdenAd P.M. Van Der Meijden , Bert Van KlingerenBert Van Klingeren , Peter A. SteerenbergPeter A. Steerenberg , Liesbeth C. De BoerLiesbeth C. De Boer , Wim H. De JongWim H. De Jong , and Frans M.J. DebruyneFrans M.J. Debruyne View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)37821-7AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Intravesical treatment with Bacillus Calmette-Guérin is an established treatment of carcinoma in situ and an effective prophylaxis for the prevention of recurrence of transitional cell carcinoma. During instillation therapy oral antibiotics may be used to prevent or to treat urinary tract infections. Tuberculostatic agents are employed to prevent or to treat local irritative symptoms and systemic side effects caused by Bacillus Calmette-Guérin. We investigated the susceptibility of four different Bacillus Calmette-Guérin preparations to 18 antibiotics and to 11 tuberculostatic agents in vitro. All preparations were equally susceptible to most of the commonly used antibiotics and to all of the tuberculostatic agents with the exception of pyrazinamide. Our results suggest that in the absence of cystitis, instillations should not be accompanied by antibiotics because of the possible inhibition of antitumor efficacy by eradication of living Bacillus Calmette-Guérin organisms. The same inhibition may occur when tuberculostatic agents are used to prevent local and systemic complications of Bacillus Calmette-Guérin instillation therapy. © 1991 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByDUREK C, RÜSCH-GERDES S, JOCHAM D and BÖHLE A (2018) INTERFERENCE OF MODERN ANTIBACTERIALS WITH BACILLUS CALMETTE-GUERIN VIABILITYJournal of Urology, VOL. 162, NO. 6, (1959-1962), Online publication date: 1-Dec-1999.Vegt P, van der Meijden A, Sylvester R, Brausi M, Holtl W and de Balincourt C (2018) Does Isoniazid Reduce Side Effects of Intravesical Bacillus Calmette-Guerin Therapy in Superficial Bladder Cancer? Interim Results of European Organization for Research and Treatment of Cancer Protocol 30911Journal of Urology, VOL. 157, NO. 4, (1246-1249), Online publication date: 1-Apr-1997.Kamat M, Kulkarni J, Tongaonkar H and Dalal A (2018) Intravesical Bacillus Calmette-Guerin For Superficial Bladder Cancer: Experience With Danish 1331 StrainJournal of Urology, VOL. 152, NO. 5 Part 1, (1424-1428), Online publication date: 1-Nov-1994.De Boer L, Steerenberg P, Van Der Meijden A, Van Klingeren B, De Jong W, Elgersma A, Debruyne F and Ruitenberg E (2018) Impaired Immune Response by Isoniazid Treatment During Intravesical BCG Administration in the Guinea PigJournal of Urology, VOL. 148, NO. 5 Part 1, (1577-1582), Online publication date: 1-Nov-1992. Volume 146Issue 2 Part 1August 1991Page: 444-446 Advertisement Copyright & Permissions© 1991 by The American Urological Association Education and Research, Inc.KeywordsneoplasmsantibioticsbladderBacillus Calmette-GuérinMetricsAuthor Information Ad P.M. Van Der Meijden More articles by this author Bert Van Klingeren More articles by this author Peter A. Steerenberg More articles by this author Liesbeth C. De Boer More articles by this author Wim H. De Jong More articles by this author Frans M.J. Debruyne More articles by this author Expand All Advertisement PDF DownloadLoading ...